STOCK TITAN
  1. Home
  2. Sec-filings
  3. RGEN
  4. [Form 4] REPLIGEN CORP Insider Trading Activity

Repligen Corp (RGEN) CEO sells 3,832 shares under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Repligen Corp Chief Executive Officer Olivier Loeillot sold 3,832 shares of common stock in an open-market transaction at $140 per share.

The sale was executed pursuant to a Rule 10b5-1 trading plan, and he continues to hold 54,246 shares of Repligen common stock directly after the transaction.

Positive

  • None.

Negative

  • None.
Insider Loeillot Olivier
Role Chief Executive Officer
Sold 3,832 shs ($536K)
Type Security Shares Price Value
Sale Common Stock 3,832 $140.00 $536K
Holdings After Transaction: Common Stock — 54,246 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares sold 3,832 shares Open-market sale on April 21, 2026
Sale price per share $140.00 per share Price reported for the April 21, 2026 sale
Shares owned after sale 54,246 shares Direct holdings following the reported transaction
Transaction date April 21, 2026 Date of CEO open-market sale
Rule 10b5-1 trading plan regulatory
"Sale of common stock was effected pursuant to a 10(b)5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: "open-market sale" for the common stock transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: "Common Stock" in the reported transaction"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Loeillot Olivier
(Last)(First)(Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/21/2026S3,832D$140(1)54,246D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on August 19th, 2025.
/s/ Jennifer Carmichael (Attorney in Fact)04/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Repligen (RGEN) report for its CEO?

Repligen reported that CEO Olivier Loeillot sold 3,832 shares of common stock in an open-market transaction. The sale was made under a Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary trade based on recent market conditions.

How many Repligen (RGEN) shares did the CEO sell and at what price?

Olivier Loeillot sold 3,832 Repligen common shares at $140 per share. This open-market sale totals roughly half a million dollars in value, based solely on the reported per-share sale price in the Form 4 transaction data for this single trade.

How many Repligen (RGEN) shares does the CEO hold after this sale?

Following the reported sale, CEO Olivier Loeillot directly owns 54,246 shares of Repligen common stock. This figure comes from the Form 4’s post-transaction holdings field and shows he retains a substantial equity position even after the open-market disposition.

Was the Repligen (RGEN) CEO’s share sale part of a Rule 10b5-1 plan?

Yes. A footnote states the sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on August 19, 2025. Such plans pre-schedule trades, helping separate routine diversification from timing decisions based on near-term information.

When did the Repligen (RGEN) CEO’s reported share sale take place?

The Form 4 lists the transaction date as April 21, 2026. On that date, CEO Olivier Loeillot completed an open-market sale of 3,832 shares at $140 per share as part of his pre-arranged Rule 10b5-1 trading plan disclosed in the filing footnote.